NorthWest Biotherapeutics Inc (NWBO)

[Dan88]

Much more optimistic than that IMHO. From the NYAS presentation it's strongly suggested if more vaccine doses can be made initially than the usual three-year of usage made and used in the trial, and if new vaccines can also be made from recurrent tumors when patients metastasize, then the overall survival of the same patient population will be much longer than those reported.

So in practice, the chance of patients living longer than those reported is much higher if more vaccine dosages are made, and new vaccines are made from recurrent tumors.

Besides, the most important thing for RAs to approve DCVax-L is much more than making available of a new treatment for nGBM and/or rGBM patients, but making available an essential agent (DCVax-L) in various combination trials such as those with Keytruda for potential cures for cancers.

Potential wise, if the approval of DCVax-L for nGBM and/or rGBM is 1, then approval of DCVax-L for other cancer indications will be 10, and the combination if successful will be 100.